{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:24:53Z","timestamp":1793395493403,"version":"4.5.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00670","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:40:51Z","timestamp":1587109251000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":359,"title":["Human Immune Responses to Adeno-Associated Virus (AAV) Vectors"],"prefix":"10.3389","volume":"11","author":[{"given":"Giuseppe","family":"Ronzitti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David-Alexandre","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles.","volume":"149","author":"Atchison","year":"1965","journal-title":"Science."},{"key":"B2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/JVI.40.1.241-247.1981","article-title":"Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication.","volume":"40","author":"Buller","year":"1981","journal-title":"J Virol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1128\/JVI.74.8.3494-3504.2000","article-title":"Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein.","volume":"74","author":"Ogston","year":"2000","journal-title":"J Virol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.44","article-title":"Vaccinia virus as a subhelper for AAV replication and packaging.","volume":"2","author":"Moore","year":"2015","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic biology of adeno-associated virus (AAV) vectors used in gene therapy.","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr Gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design.","volume":"366","author":"Ogden","year":"2019","journal-title":"Science."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-associated virus antibody profiles in newborns, children, and adolescents.","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).","volume":"59","author":"Erles","year":"1999","journal-title":"J Med Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.","volume":"19","author":"Li","year":"2011","journal-title":"Gene Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: virus versus vector.","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Ther."},{"key":"B11","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.gt.3300680","article-title":"Adeno-associated virus vectors can be efficiently produced without helper virus.","volume":"5","author":"Matsushita","year":"1998","journal-title":"Gene Ther."},{"key":"B12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1089\/hum.1998.9.18-2745","article-title":"Novel tools for production and purification of recombinant adenoassociated virus vectors.","volume":"9","author":"Grimm","year":"1998","journal-title":"Hum Gene Ther."},{"key":"B13","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1089\/hum.1998.9.16-2353","article-title":"High-titer adeno-associated viral vectors from a Rep\/Cap cell line and hybrid shuttle virus.","volume":"9","author":"Gao","year":"1998","journal-title":"Hum Gene Ther."},{"key":"B14","doi-asserted-by":"crossref","first-page":"8780","DOI":"10.1128\/JVI.71.11.8780-8789.1997","article-title":"Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.","volume":"71","author":"Conway","year":"1997","journal-title":"J Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1089\/hum.2009.004","article-title":"Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells.","volume":"20","author":"Thomas","year":"2009","journal-title":"Hum Gene Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/bit.23028","article-title":"Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals.","volume":"108","author":"Marek","year":"2011","journal-title":"Biotechnol Bioeng."},{"key":"B17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/gt.2008.65","article-title":"Manufacturing and characterizing AAV-based vectors for use in clinical studies.","volume":"15","author":"Wright","year":"2008","journal-title":"Gene Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/B978-0-12-386509-0.00012-0","article-title":"Adeno-associated virus vectorology, manufacturing, and clinical applications.","volume":"507","author":"Grieger","year":"2012","journal-title":"Methods Enzymol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gt.2009.157","article-title":"High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency.","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","article-title":"Pharmacology of recombinant adeno-associated virus production.","volume":"8","author":"Penaud-Budloo","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/156652310793180715","article-title":"Manufacturing and regulatory strategies for clinical AAV2-hRPE65.","volume":"10","author":"Wright","year":"2010","journal-title":"Curr Gene Ther."},{"key":"B22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/156652310793797685","article-title":"Production, purification and characterization of adeno-associated vectors.","volume":"10","author":"Ayuso","year":"2010","journal-title":"Curr Gene Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ymthe.2019.11.014","article-title":"The effect of CpG sequences on capsid-specific CD8(+) T cell responses to AAV vector gene transfer.","volume":"28","author":"Xiang","year":"2019","journal-title":"Mol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications.","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol Ther."},{"key":"B25","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/mt.2012.220","article-title":"rAAV-mediated tumorigenesis: still unresolved after an AAV assault.","volume":"20","author":"Valdmanis","year":"2012","journal-title":"Mol Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model.","volume":"117","author":"Li","year":"2011","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/mt.2008.103","article-title":"Recombinant adeno-associated virus transduction and integration.","volume":"16","author":"Schultz","year":"2008","journal-title":"Mol Ther."},{"key":"B28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors.","volume":"5","author":"Gao","year":"2005","journal-title":"Curr Gene Ther."},{"key":"B29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JVI.76.2.791-801.2002","article-title":"Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.","volume":"76","author":"Rabinowitz","year":"2002","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.4049\/jimmunol.0803965","article-title":"Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins.","volume":"182","author":"Mays","year":"2009","journal-title":"J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy.","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat Rev Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads.","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol Ther."},{"key":"B33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/138620708783744507","article-title":"Artificial evolution with adeno-associated viral libraries.","volume":"11","author":"Perabo","year":"2008","journal-title":"Comb Chem High Throughput Screen."},{"key":"B34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/JVI.80.1.426-439.2006","article-title":"Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.","volume":"80","author":"Grimm","year":"2006","journal-title":"J Virol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00009","article-title":"Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors.","volume":"5","author":"Tseng","year":"2014","journal-title":"Front Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"27053","DOI":"10.1073\/pnas.1910061116","article-title":"A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism.","volume":"116","author":"Davidsson","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/mt.2009.245","article-title":"The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.","volume":"18","author":"Wang","year":"2010","journal-title":"Mol Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age-related seroprevalence of antibodies against AAV-LK03 in a UK population Cohort.","volume":"30","author":"Perocheau","year":"2019","journal-title":"Hum Gene Ther."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.03.004","article-title":"Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in duchenne muscular dystrophy patients.","volume":"342","author":"Leborgne","year":"2019","journal-title":"Cell Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international Cohorts of healthy donors.","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jmv.21360","article-title":"Diverse IgG subclass responses to adeno-associated virus infection and vector administration.","volume":"81","author":"Murphy","year":"2009","journal-title":"J Med Virol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction.","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B44","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med."},{"key":"B46","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts.","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors.","volume":"82","author":"Zaiss","year":"2008","journal-title":"J Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"10784","DOI":"10.1128\/JVI.01813-13","article-title":"C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice.","volume":"87","author":"Denard","year":"2013","journal-title":"J Virol."},{"key":"B50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans.","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1172\/JCI122372","article-title":"Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.","volume":"128","author":"Kuranda","year":"2018","journal-title":"J Clin Invest."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/mt.2011.81","article-title":"Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates.","volume":"19","author":"Li","year":"2011","journal-title":"Mol Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ymthe.2019.11.014","article-title":"The effect of CpG sequences on capsid-specific CD8+ T cell responses to AAV vector gene transfer.","volume":"28","author":"ZhiQuan","year":"2019","journal-title":"Mol Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1089\/hgtb.2018.038","article-title":"Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors.","volume":"29","author":"Calcedo","year":"2018","journal-title":"Hum Gene Ther Methods."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.29","article-title":"AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes.","volume":"2","author":"Hui","year":"2015","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-61779-370-7_11","article-title":"Measuring immune responses to recombinant AAV gene transfer.","volume":"807","author":"Martino","year":"2011","journal-title":"Methods Mol Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.4049\/jimmunol.1200620","article-title":"Humoral and cellular capsid-specific immune responses to adeno-associated virus Type 1 in randomized healthy donors.","volume":"188","author":"Veron","year":"2012","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03110","article-title":"Tetramer-based enrichment of preexisting anti-AAV8 CD8(+) T cells in human donors allows the detection of a TEMRA subpopulation.","volume":"10","author":"Vandamme","year":"2019","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood."},{"key":"B61","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.immuni.2012.01.002","article-title":"Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes.","volume":"36","author":"Newell","year":"2012","journal-title":"Immunity."},{"key":"B62","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1128\/JVI.00529-07","article-title":"Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.","volume":"81","author":"Li","year":"2007","journal-title":"J Virol."},{"key":"B63","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.mt.6300090","article-title":"Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.","volume":"15","author":"Li","year":"2007","journal-title":"Mol Ther."},{"key":"B64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/hum.2007.001","article-title":"Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets.","volume":"18","author":"Wang","year":"2007","journal-title":"Hum Gene Ther."},{"key":"B65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nri2038","article-title":"Cooperation of Toll-like receptor signals in innate immune defence.","volume":"7","author":"Trinchieri","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T cells.","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood."},{"key":"B67","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ymthe.2019.11.011","article-title":"Type I IFN sensing by cDCs and CD4(+) T cell help are both requisite for cross-priming of AAV capsid-specific CD8(+) T Cells.","volume":"28","author":"Shirley","year":"2019","journal-title":"Mol Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors.","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.","volume":"117","author":"Martino","year":"2011","journal-title":"Blood."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.07.012","article-title":"Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.","volume":"342","author":"Herzog","year":"2019","journal-title":"Cell Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer.","volume":"7","author":"Rogers","year":"2015","journal-title":"J Innate Immun."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B.","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med."},{"key":"B75","author":"Abbas","year":"2009","journal-title":"Basic Immunology: Functions and Disorders of the Immune System."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.","volume":"119","author":"Pien","year":"2009","journal-title":"J Clin Invest."},{"key":"B77","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.omtm.2017.04.004","article-title":"An immune-competent murine model to study elimination of AAV-transduced hepatocytes by capsid-specific CD8(+) T cells.","volume":"5","author":"Palaschak","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant.","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun."},{"key":"B80","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.33","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study.","volume":"1","author":"Corti","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.","volume":"18","author":"Finn","year":"2010","journal-title":"Mol Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.omtm.2018.10.012","article-title":"AAV8 gene therapy for crigler-najjar syndrome in macaques elicited transgene T cell responses that are resident to the liver.","volume":"11","author":"Greig","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy.","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1073\/pnas.1617726114","article-title":"Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency.","volume":"114","author":"Calcedo","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ymthe.2017.03.029","article-title":"5 Year Expression and neutrophil defect repair after gene therapy in Alpha-1 antitrypsin deficiency.","volume":"25","author":"Mueller","year":"2017","journal-title":"Mol Ther."},{"key":"B88","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial.","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.omtm.2019.08.012","article-title":"Role of regulatory T cell and effector T cell exhaustion in liver-mediated transgene tolerance in muscle.","volume":"15","author":"Poupiot","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B90","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity.","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B91","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/1566523215666150630121750","article-title":"The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer.","volume":"15","author":"Boisgerault","year":"2015","journal-title":"Curr Gene Ther."},{"key":"B92","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.","volume":"110","author":"Cao","year":"2007","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127008","article-title":"Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity.","volume":"4","author":"Bartolo","year":"2019","journal-title":"JCI Insight."},{"key":"B95","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4049\/jimmunol.172.2.1009","article-title":"Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.","volume":"172","author":"Pillarisetty","year":"2004","journal-title":"J Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/hep.22395","article-title":"Mechanism of T cell tolerance induction by murine hepatic Kupffer cells.","volume":"48","author":"You","year":"2008","journal-title":"Hepatology."},{"key":"B97","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0168-8278(95)80433-1","article-title":"Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge.","volume":"22","author":"Knolle","year":"1995","journal-title":"J Hepatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.4049\/jimmunol.1700540","article-title":"TLR2 stimulation strengthens intrahepatic myeloid-derived cell-mediated T cell tolerance through inducing Kupffer cell expansion and IL-10 production.","volume":"200","author":"Liu","year":"2018","journal-title":"J Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/hep.23043","article-title":"Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver.","volume":"50","author":"Breous","year":"2009","journal-title":"Hepatology (Baltimore, Md.)."},{"key":"B100","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","article-title":"Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming.","volume":"574","author":"B\u00e9n\u00e9chet","year":"2019","journal-title":"Nature."},{"key":"B101","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The balance between CD8 + T Cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose.","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"E2540","DOI":"10.1073\/pnas.1406674111","article-title":"Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses.","volume":"111","author":"Tay","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B103","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2008.05.078","article-title":"Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death.","volume":"135","author":"Holz","year":"2008","journal-title":"Gastroenterology."},{"key":"B104","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1189\/jlb.2AB0613-342RR","article-title":"Hepatocytes induce Foxp3(+) regulatory T cells by notch signaling.","volume":"96","author":"Burghardt","year":"2014","journal-title":"J Leukoc Biol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.4049\/jimmunol.1300826","article-title":"Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells.","volume":"191","author":"Burghardt","year":"2013","journal-title":"J Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/mt.2009.301","article-title":"BALB\/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver.","volume":"18","author":"Breous","year":"2010","journal-title":"Mol Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/blood-2014-09-599266","article-title":"Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell\u2013dependent induction of CD4+CD25+FoxP3+ Treg.","volume":"125","author":"Biswas","year":"2015","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymthe.2017.09.001","article-title":"Gene therapy-induced antigen-specific tregs inhibit neuro-inflammation and reverse disease in a mouse model of multiple sclerosis.","volume":"26","author":"Keeler","year":"2018","journal-title":"Mol Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jhep.2016.11.019","article-title":"Alloantigen gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8(+) regulatory T cells.","volume":"66","author":"Le","year":"2017","journal-title":"J Hepatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"16735","DOI":"10.1073\/pnas.1112251108","article-title":"Hepatocyte entry leads to degradation of autoreactive CD8 T cells.","volume":"108","author":"Benseler","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B111","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood-2004-03-0847","article-title":"Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer.","volume":"104","author":"Dobrzynski","year":"2004","journal-title":"Blood."},{"key":"B112","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/blood-2006-03-010181","article-title":"Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.","volume":"109","author":"Nathwani","year":"2007","journal-title":"Blood."},{"key":"B114","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","article-title":"Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.","volume":"8","author":"McCarty","year":"2001","journal-title":"Gene Ther."},{"key":"B115","article-title":"AAV8-FIX long term follow up and future plans","author":"Reiss","year":"2019","journal-title":"Proceedings of the Oral Presentation National Hemophilia Foundation\u2019s 15th Workshop on Novel Technologies and Gene Transfer for Hemophilia 2019."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene transfer in severe Hemophilia A.","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ gene therapy for Hemophilia A.","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther."},{"key":"B120","article-title":"Whole exome sequencing of patients treated with adeno-associated virus serotype 8-factor IX (AAV8-FIX) gene therapy reveals potential determinants of persistent transgene expression.","author":"Bilic","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"key":"B121","article-title":"Increased immunogenicity of CpG containing adeno-associated virus serotype 8 (AAV8) constructs might contribute to the drop of transgene expression.","author":"Koppensteiner","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"key":"B122","article-title":"101HEMB01 is a phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with moderate\/severe Hemophilia B that demonstrated meaningful but transient expression of human factor IX (hFIX).","author":"Pipe","year":"2017","journal-title":"Blood."},{"key":"B123","article-title":"Immune responses in 101HEMB01, a Phase 1\/2 open-label, single ascending dose-finding trial of DTX101 (AAVrh10FIX) in patients with severe Hemophilia B.","author":"Calcedo","year":"2017","journal-title":"Blood."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval.","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy.","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"B126","doi-asserted-by":"crossref","DOI":"10.1016\/S1525-0016(16)33289-0","article-title":"Gene therapy for spinal muscular atrophy Type 1 shows potential to improve survival and motor functional outcomes.","author":"Mendell","year":"2016","journal-title":"Mol Ther."},{"key":"B127","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy.","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy.","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B129","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2019.06.594","article-title":"Intrathecal administration of onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): phase 1\/2a study (STRONG).","author":"Finkel","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B130","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN.","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B131","year":"2019","journal-title":"AveXis Issues Community Statement on AVXS-101 Clinical Hold."},{"key":"B132","first-page":"S37","article-title":"ASPIRO phase 1\/2 gene therapy trial in X-linked motubular myopathy (XLMTM): update on preliminary safety and efficacy findings. 24th World Muscle Society Meeting 2019.","volume":"29","author":"Dowling","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B133","article-title":"Neuromuscular targeted therapies","author":"Rodino-Klapac","year":"2019","journal-title":"Proceedings of the 22nd Annual Meeting: Final Program Guide."},{"key":"B134","year":"2019","journal-title":"Solid Biosciences Provides SGT-001 Program Update."},{"key":"B135","year":"2019","journal-title":"Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:41:01Z","timestamp":1587109261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2020.00670"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00670","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"article-number":"670"}}